FDA Says 505(q) Petitions Pull Resources from Safety Activities

Drug GMP Report
Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agency’s public health efforts, the FDA said in a report to Congress.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00